Pharvaris N.V. (NASDAQ: PHVS) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
35.09
+0.18+0.52%
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 1.72% | Shs Outstand | 69.88M | Perf Week | 7.02% |
| Market Cap | 2.44B | Forward P/E | - | EPS next Y | -2.88 | Insider Trans | -32.61% | Shs Float | 33.19M | Perf Month | -2.92% |
| Enterprise Value | 2.16B | PEG | 3.75 | EPS next Q | - | Inst Own | - | Short Float | 1.63% | Perf Quarter | 17.62% |
| Income | -209.34M | P/S | 0.00 | EPS this Y | - | Inst Trans | - | Short Ratio | 2.69 | Perf Half Y | 38.86% |
| Sales | 0.00 | P/B | 8.35 | EPS next Y | 6.62% | ROA | -65.13% | Short Interest | 1.14M | Perf YTD | 25.80% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -67.40% | 52W High | 36.79 -4.62% | Perf Year | 64.44% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -72.82% | 52W Low | 19.66 78.48% | Perf 3Y | 104.99% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 0.00% | Volatility | 4.87% 4.54% | Perf 5Y | 96.45% |
| Dividend TTM | - | EV/Sales | 0.00 | EPS Y/Y TTM | -20.38% | Oper. Margin | 0.00% | ATR (14) | 1.61 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 11.24 | Sales Y/Y TTM | - | Profit Margin | 0.00% | RSI (14) | 56.02 | Recom | 2.08 |
| Dividend Gr. 3/5Y | - | Current Ratio | 11.24 | EPS Q/Q | 17.65% | SMA20 | 2.88% | Beta | -2.44 | Target Price | 52.00 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | - | SMA50 | 5.46% | Rel Volume | 1.64 | Prev Close | 34.91 |
| Employees | 134 | LT Debt/Eq | 0.00 | Earnings | Aug 11 | SMA200 | 23.53% | Avg Volume | 425.89K | Price | 35.09 |
| IPO Date | Feb 04, 2021 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 16.26% - | Net Debt/EBITDA | 1.48 | Volume | 696,380 | Change | 0.52% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-15-26 | Initiated | Wells Fargo | Overweight | $55 |
| Jun-25-26 | Reiterated | Morgan Stanley | Overweight | $41 → $46 |
| May-13-26 | Reiterated | UBS | $75 → $74 | |
| Apr-08-26 | Initiated | Wolfe Research | Outperform | $42 |
| Mar-09-26 | Initiated | RBC Capital | Outperform | $52 |
| Dec-04-25 | Reiterated | Morgan Stanley | Overweight | $41 |
| Dec-04-25 | Reiterated | Guggenheim | Buy | $39 |
| Dec-04-25 | Reiterated | Oppenheimer | Outperform | $42 → $50 |
| Dec-03-25 | Reiterated | Leerink Partners | $28 → $38 | |
| Oct-15-25 | Initiated | H.C | Buy | $60 |
Latest News
Aug-06-26
Aug-06-2606:50AM
Aug-04-26
Jul-31-26
Jul-31-2610:56AM
Jul-24-26
Jul-24-2607:01AM
Jul-22-26
Jul-22-2606:53AM
06:50AM
Jul-15-26
07:03AM
Jul-14-26
Jul-14-2610:56AM
Jul-06-26
Jul-06-2606:53AM
06:50AM
Jun-25-26
Jun-25-2601:33PM
Jun-15-26
Jun-15-2606:52AM
Jun-12-26
Jun-12-2607:13PM
Company
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | — | — | — | — | — | |
| Gross Profit | 0 | 0 | 0 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 51 | 51 | 34 | — | — | — | — | — | |
| Research and Development | 140 | 107 | 71 | — | — | — | — | — | |
| Other Operating Expense | 1 | 0 | 0 | — | — | — | — | — | |
| Operating Income | -192 | -158 | -105 | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -4 | 14 | -3 | — | — | — | — | — | |
| Net Income Before Taxes | -196 | -143 | -108 | — | — | — | — | — | |
| Income Taxes | 2 | 2 | 1 | — | — | — | — | — | |
| Consolidated Net Income | -198 | -145 | -109 | — | — | — | — | — | |
| Net Income From Continuing Operations | -198 | -145 | -109 | — | — | — | — | — | |
| Net Income | -198 | -145 | -109 | — | — | — | — | — | |
| EPS (Recurring) | -3.35 | -2.68 | -2.84 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -3.35 | -2.68 | -2.84 | — | — | — | — | — | |
| EPS (Diluted) | -3.35 | -2.68 | -2.84 | — | — | — | — | — | |
| EBITDA | -195 | -158 | -108 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | |
| Shares Outstanding | 59 | 54 | 38 | — | — | — | — | — | |
| Market Capitalization | 1,637 | 1,035 | 1,066 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Modig Berndt | Chief Executive Officer | Jul 13 '26 | Sale | 34.97 | 2,292 | 80,154 | 132,917 | Jul 15 |
| Lesage Anne | Chief Early Development | Jun 30 '26 | Option Exercise | 7.47 | 27,872 | 208,142 | 86,622 | Jul 01 |
| Schikan Johannes Gerardus Christiaan Petrus | Director | Jun 30 '26 | Sale | 35.49 | 30,712 | 1,090,049 | 315,167 | Jul 01 |
| Lesage Anne | Chief Early Development | Jun 30 '26 | Sale | 35.48 | 58,575 | 2,078,527 | 58,750 | Jul 01 |
| Lesage Anne | Chief Early Development | Jun 29 '26 | Option Exercise | 5.22 | 10,600 | 55,300 | 67,050 | Jul 01 |
| Schikan Johannes Gerardus Christiaan Petrus | Director | Jun 29 '26 | Sale | 35.07 | 9,288 | 325,697 | 345,879 | Jul 01 |
| Lesage Anne | Chief Early Development | Jun 29 '26 | Sale | 35.06 | 17,597 | 616,926 | 56,450 | Jul 01 |
| Lu Peng | Chief Medical Officer | Jun 26 '26 | Sale | 34.00 | 14,700 | 499,847 | 65,631 | Jun 29 |
| Lu Peng | Chief Medical Officer | Jun 26 '26 | Option Exercise | 2.59 | 14,700 | 38,073 | 80,331 | Jun 29 |
| Lesage Anne | Chief Early Development | Jun 25 '26 | Sale | 35.12 | 4,600 | 161,561 | 56,450 | Jun 29 |
| Lesage Anne | Chief Early Development | Jun 25 '26 | Option Exercise | 4.73 | 2,300 | 10,871 | 58,750 | Jun 29 |
| Lu Peng | Chief Medical Officer | Jun 25 '26 | Option Exercise | 2.59 | 15,000 | 38,850 | 80,631 | Jun 29 |
| Lu Peng | Chief Medical Officer | Jun 25 '26 | Sale | 34.60 | 15,000 | 518,985 | 65,631 | Jun 29 |
| Lu Peng | Chief Medical Officer | Jun 18 '26 | Option Exercise | 2.59 | 300 | 777 | 65,931 | Jun 23 |
| Lu Peng | Chief Medical Officer | Jun 18 '26 | Sale | 34.00 | 300 | 10,200 | 65,631 | Jun 23 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.